- Proven technology platform based on proprietary fluorination chemistry leading to a pipeline of products across a broad range of applications in cosmetics and pharmaceuticals.
- Signed global exclusive licensing deal with Allergan Aesthetics, an AbbVie [NYSE: ABBV] company, for TFC-1067 and library of cosmetic compounds.
- Ongoing royalty payments for compound discoveries, including upcoming royalties on net sales generated by AbbVie product line based on licensed patented ingredients. Cooperating on additional products with AbbVie. Seventeen years duration for TFC-1067 patents.
- Disruptive proprietary carbohydrate-bonding platform based on 20 years of research and development.
- Strong worldwide IP portfolio, including North America, European Union and Asia.
- Cosmetics - Developing disruptive solutions for anti-aging (US$271 billion), cell preservation (US$7.5 billion), and cellulite treatment (US$1.4 billion).
- TFC-039, first-in-market ingestible tablet to treat animal diabetes. In advanced partnership talks with three major animal health companies.
- Developing antiviral TBD compound for US$36 billion antiviral market.
- State-of-the-art, multi-million dollar laboratory in France with top scientific team, strong global manufacturing partners for pharmaceutical (Wanbang Pharma, China) and cosmetics (Wuxi AppTec, China).
Sirona Biochem Inc. (TSXV:SBM) is a biotechnology company with an innovative platform for developing safer, more effective cosmetic and pharmaceutical active ingredients. Its strategy is to license or sell its patented compounds to leading global companies in return for up-front fees, milestone fees and ongoing royalty payments.
Sirona’s technology is based on proprietary fluorination chemistry developed by the company’s wholly owned French subsidiary research and development (R&D) laboratory TFChem. This fluorination chemistry can improve the safety and efficacy of carbohydrate-based molecules, which have broad application potential for the development of pharmaceuticals and cosmeceuticals. Examples of commercially available carbohydrate-based drugs include viral neuraminidase inhibitor Tamiflu, and Johnson & Johnson’s (NYSE:JNJ) SGLT2 inhibitor Invokana™.
Carbohydrate-based molecules are extremely challenging to develop due to their inherent instability. Sirona’s proprietary chemistry technique overcomes that challenge by stabilizing carbohydrates, allowing the company to explore commercial opportunities for these valuable molecules.